SCHEMBL26090441

SCHEMBL26090441

CC(C)(C)OC(=O)N1CCN(c2nc(C=O)c[nH]2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 1/20 0.44
▸ CKS1B P61024 2/20 0.43
▸ SKP1 P63208 2/20 0.43
▸ SKP2 Q13309 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ ACHE P22303 2/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ NAMPT P43490 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ GPR119 Q8TDV5 3/20 0.40
▸ KIT P10721 1/20 0.39
▸ SMARCA2 P51531 1/20 0.39
▸ SMARCA4 P51532 1/20 0.39
▸ PBRM1 Q86U86 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ GBA1 P04062 1/20 0.39
▸ PTPN11 Q06124 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22322235 0.75 GPR119 (0.46) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL11916784 0.75 CKS1B (0.43) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL27202974 0.75 CKS1B (0.46) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL26094150 0.75 CKS1B (0.43) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL25201029 0.74 MAPT (0.50) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL25821197 0.74 CKS1B (0.45) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL30427515 0.74 MAPT (0.50) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL21005939 0.73 CKS1B (0.55) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL16825695 0.73 MAP4K4 (0.46) KCNH2CKS1BSKP1SKP2ALDH1A1
Hydrochloric Acid SCHEMBL29169344 0.72 CKS1B (0.54) CKS1BSKP1SKP2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 — — EP disclosed
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2025-07-17 — — US disclosed
EP-4419525-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2024-08-28 — — EP disclosed
CN-118556059-A Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-08-27 — — CN disclosed
WO-2023067353-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 — — WO disclosed
WO-2023067353-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NQO1, VHL, SDHA KCNH2 3363/4885CKS1B 1697/4885SKP1 1099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback